There is no ordinary pharmacy compounding route for ipamorelin or CJC-1295 in the current FDA record. Authorized investigational use is a separate framework. If you came from a results claim, the results evidence guide explains what the studies measured.
No legal route means no prescription a pharmacy can fill
A prescription only works if a pharmacy can lawfully make the drug. For a compounded peptide, that pharmacy needs the ingredient to be FDA-approved, covered by a USP monograph, or on the 503A bulks list. Ipamorelin and CJC-1295 meet none of those.
A routine prescription does not create an eligible compounding ingredient. Commercial compounding is separate from properly authorized investigational use under FDA’s IND framework; a trial registry entry alone is not that authorization [1].
FDA's record on both peptides, date by date
| Date | Ipamorelin | CJC-1295 | Source |
|---|---|---|---|
| September 29, 2023 | 503A Category 2 (acetate); 503B Category 2 | 503A Category 2 | FDA 503A list [3]; FDA safety-risks page [9] |
| September 27, 2024 | Nominations withdrawn; removed from 503A Category 2 | Nominations withdrawn; removed from 503A Category 2 | FDA 503A list [4] |
| October 29, 2024 | Advisers vote on FDA's proposal not to list it: 0 for listing, 12 against, 1 abstention (both forms) | Not on that meeting's agenda | Meeting transcript [5] |
| December 4, 2024 | Already voted on | Advisers vote on FDA's proposal not to list it: free base 0 for, 13 against; acetate 1 for, 12 against; three DAC forms 0 for, 13 against | Meeting minutes [7] |
| April 22, 2026 | Still 503B Category 2; also in FDA's "nominated but withdrawn" table | In FDA's "nominated but withdrawn" table | FDA safety-risks page [9] |
| May 14, 2026 | In no 503A category | In no 503A category | FDA 503A list [2] |
A "no" vote was a vote for FDA's proposal to keep the substance off the 503A bulks list. As of this update, FDA hasn't issued a final rule adding either one.
Ipamorelin: FDA's advisers voted 0 to 12 against listing it
On October 29, 2024, FDA proposed not adding ipamorelin to the 503A bulks list. Its compounding advisers agreed: 0 votes for listing, 12 against and 1 abstention, for both the free base and the acetate [5]. FDA's briefing noted there's no USP monograph for either form, and neither is part of an approved drug [6].
The path there matters. FDA placed ipamorelin acetate in 503A Category 2, substances that may pose significant safety risks, in September 2023 [3]. The nominators withdrew in September 2024, which removed it from that category [4]. FDA took it to the committee anyway, and announced the meeting in the Federal Register that month [10]. For outsourcing facilities, ipamorelin acetate is still in Category 2 [9].
Its human evidence is thin. Its one patient trial, in 114 people after bowel surgery, found no significant difference from placebo [12].
CJC-1295: the advisers voted against all five forms
CJC-1295 followed the same path. It entered 503A Category 2 in September 2023 and left it when the nominations were withdrawn a year later [4]. FDA announced a committee review in October 2024 [11]. On December 4, 2024, the committee voted on five CJC-1295 forms, with and without the long-acting "DAC" add-on. For four, the vote was 13 against listing and none for. For the acetate it was 12 against and 1 for [7]. FDA's briefing found no USP monograph for any form, and none is part of an approved drug [8].
FDA's safety page says it has identified serious adverse events with CJC-1295. They include a faster heart rate and a body-wide reaction from widened blood vessels. FDA adds that clinical data are limited [9].
If a clinic offers them anyway, ask which pharmacy and under which list
A clinic offering compounded ipamorelin or CJC-1295 is offering something FDA's record gives no route for. That includes blends, such as a "CJC-1295 and ipamorelin" vial or a sermorelin blend with ipamorelin in it. Sermorelin and ipamorelin together covers that pairing.
- Which pharmacy makes this, and is it a 503A pharmacy or a 503B outsourcing facility?
- Under which list or monograph is the ingredient allowed?
- Who is the prescribing clinician, and is that person licensed in my state?
- What would you offer me if this product weren't available?
A vague answer to any of those is your answer.
"Research use only" vials aren't sold for people
Research-labeled vials are sold outside the drug system. The label itself says they aren't for human use. No prescriber reviews you, and no pharmacy answers for what's in the vial.
- No prescription, questionnaire or clinician before checkout.
- "Not for human consumption" printed on the label or the page.
- Payment by crypto, gift card or an app transfer.
- A lab certificate offered as the sole proof of quality.
FDA's concern with these peptides is about quality as much as effect. Its safety listings cite possible immune reactions from impurities and clumping in compounded peptides [9].
The legal growth-hormone option is sermorelin, by prescription
For growth hormone support, a prescriber can offer sermorelin, a compounded GHRH analog that was once FDA-approved as Geref. How to get sermorelin prescribed covers the steps, and our sermorelin cost guide compares programs. Its adult evidence is small too, so set expectations.
Tesamorelin is FDA-approved, but only as a brand drug for reducing excess belly fat in adults with HIV and lipodystrophy [13]. It can't be compounded either, which can you get tesamorelin legally explains.
Or start from the goal. The hormones shortlist covers hormone care, the sleep and recovery shortlist covers rest, and the body composition shortlist covers muscle and fat.